| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1053/SONC.2002.35525 |
| P698 | PubMed publication ID | 12422305 |
| P50 | author | Erick Gamelin | Q114435588 |
| P2093 | author name string | Stefan Quasthoff | |
| Laura Bossi | |||
| Laurence Gamelin | |||
| P433 | issue | 5 Suppl 15 | |
| P921 | main subject | oxaliplatin | Q422327 |
| neurotoxicity | Q3338704 | ||
| toxic encephalopathy | Q7830379 | ||
| P304 | page(s) | 21-33 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures | |
| P478 | volume | 29 |
| Q57220984 | Q57220984 |
| Q36825624 | 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates in vitro and in vivo antitumor effects of irinotecan on human colorectal cancer cells |
| Q46501921 | A Phase II study of oxaliplatin in urothelial cancer |
| Q28484947 | A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy |
| Q34321665 | A novel behavioral assay for measuring cold sensation in mice |
| Q36704820 | A phosphotyrosine switch regulates organic cation transporters |
| Q28534748 | A polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in rats |
| Q37730640 | A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in South Africa in patients with metastatic colorectal cancer |
| Q46694167 | A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance |
| Q35906940 | A review of oxaliplatin and its clinical use in colorectal cancer |
| Q41231820 | Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. |
| Q37955698 | Acute pain associated with oxaliplatin infusion: case report and literature review. |
| Q36503798 | Advances in the adjuvant treatment of colorectal cancer |
| Q35815721 | Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure |
| Q33800645 | Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) |
| Q37111987 | Assessment of nerve excitability in toxic and metabolic neuropathies |
| Q34267113 | Attenuation of activity in an endogenous analgesia circuit by ongoing pain in the rat |
| Q43218273 | Atypical presentation of acute neurotoxicity secondary to oxaliplatin |
| Q42361415 | Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy |
| Q40071911 | Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? |
| Q36614800 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial |
| Q38626963 | Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer |
| Q42022293 | Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. |
| Q50103900 | Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study. |
| Q58455979 | Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies |
| Q52648842 | Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. |
| Q37659699 | Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. |
| Q38370562 | Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. |
| Q34653461 | Chemotherapy-induced polyneuropathy. Part I. Pathophysiology |
| Q60305401 | Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective |
| Q36638304 | Combined Effects of Bee Venom Acupuncture and Morphine on Oxaliplatin-Induced Neuropathic Pain in Mice |
| Q37341155 | Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. |
| Q44696954 | Contribution of Piezo2 to endothelium-dependent pain |
| Q40631806 | Cyclopalladated compounds as chemotherapeutic agents: Antitumor activity against a murine melanoma cell line |
| Q35843703 | Developments in combination chemotherapy for colorectal cancer |
| Q55031561 | Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients. |
| Q34683946 | Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. |
| Q44909373 | Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer |
| Q33873552 | Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity |
| Q36350645 | Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial |
| Q47609223 | Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer |
| Q37154821 | Effect of bee venom acupuncture on oxaliplatin-induced cold allodynia in rats |
| Q34380468 | Effect of green tea extracts on oxaliplatin-induced peripheral neuropathy in rats |
| Q42031749 | Effect of neurosteroid modulation on global ischaemia-reperfusion-induced cerebral injury in mice |
| Q38445554 | Effects of electroacupuncture on oxaliplatin-induced neuropathic cold hypersensitivity in rats. |
| Q33774892 | Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysis |
| Q37338244 | Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients |
| Q35103028 | Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer |
| Q92276494 | Enhancement of oxaliplatin-induced colon cancer cell apoptosis by alantolactone, a natural product inducer of ROS |
| Q38707400 | Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q37419104 | Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer |
| Q47096826 | Guillain-Barre Syndrome Associated with Gastric Cancer: Paraneoplastic Syndrome or Immunological Disorder? |
| Q34610876 | Gyejigachulbu-Tang Relieves Oxaliplatin-Induced Neuropathic Cold and Mechanical Hypersensitivity in Rats via the Suppression of Spinal Glial Activation. |
| Q43276118 | Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? |
| Q39192289 | Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties |
| Q50956973 | Impact of oxaliplatin-induced neuropathy: a patient perspective. |
| Q37060295 | Involvement of spinal muscarinic and serotonergic receptors in the anti-allodynic effect of electroacupuncture in rats with oxaliplatin-induced neuropathic pain |
| Q38087423 | Liposomes, a promising strategy for clinical application of platinum derivatives |
| Q35584874 | Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility |
| Q35210263 | Longitudinal assessment of oxaliplatin-induced neuropathy. |
| Q33604447 | Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial |
| Q36533867 | Management of advanced colorectal cancer: state of the art. |
| Q35166744 | Management of oxaliplatin-induced peripheral neuropathy. |
| Q55265662 | Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis. |
| Q26998870 | Mechanisms of chemotherapy-induced behavioral toxicities |
| Q30446860 | Membrane transporters as mediators of Cisplatin effects and side effects |
| Q36893806 | Metastatic colorectal cancer-past, progress and future |
| Q35758048 | Molecular mechanisms of resistance and toxicity associated with platinating agents |
| Q35019148 | Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice |
| Q89910592 | Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale |
| Q84290931 | Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial |
| Q35692169 | Neurotoxicity caused by the treatment with platinum analogues |
| Q36788436 | Oxaliplatin in the treatment of colorectal cancer |
| Q35160434 | Oxaliplatin neurotoxicity of sensory transduction in rat proprioceptors |
| Q43183942 | Oxaliplatin neurotoxicity--no general ion channel surface-charge effect. |
| Q33389165 | Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer |
| Q36740632 | Oxaliplatin-DNA adduct formation in white blood cells of cancer patients |
| Q88603422 | Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer |
| Q35980222 | Oxaliplatin-associated neuropathy: a review |
| Q39803653 | Oxaliplatin-induced neuropathy in colorectal cancer |
| Q35931656 | Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation |
| Q43278321 | Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. |
| Q46787006 | Oxaliplatin-related neurotoxicity: is chelation the solution? |
| Q38937300 | PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects |
| Q44317716 | Palliative treatment for colorectal cancer |
| Q48067734 | Patient-reported outcomes in long-term survivors of metastatic colorectal cancer needing liver resection |
| Q35603872 | Peripheral neuropathy and cancer |
| Q60678660 | Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings |
| Q33780411 | Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors |
| Q35025710 | Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. |
| Q46990345 | Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). |
| Q43256423 | Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags |
| Q54409428 | Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity |
| Q33841734 | Predicting acute and persistent neuropathy associated with oxaliplatin |
| Q35544078 | Review article: colorectal cancer chemotherapy |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q35168122 | Role of Drp1, a key mitochondrial fission protein, in neuropathic pain |
| Q37808196 | Role of Erythropoeitin in Prevention of Chemotherapy-induced Peripheral Neuropathy |
| Q34133825 | Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy |
| Q38474594 | Role of transporters in the distribution of platinum-based drugs |
| Q47161067 | SCORE: Shared care of Colorectal cancer survivors: protocol for a randomised controlled trial |
| Q45837121 | Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers |
| Q38729844 | Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial. |
| Q24815800 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer |
| Q87383865 | Synthesis, cytotoxicity, induction of apoptosis, and interaction with DNA of dinuclear platinum(II) complexes |
| Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
| Q47326759 | The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen |
| Q38888345 | The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations |
| Q82462847 | The current state of the drugs for the treatment of peripheral neuropathy induced by anticancer drugs |
| Q37031281 | The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial |
| Q37410573 | Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir |
| Q46813516 | UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen |
| Q56777795 | Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer |
Search more.